Gut-associated Lymphoid Tissue Attrition Associates with Response to Anti-α4β7 Therapy in Ulcerative Colitis

Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct cohorts of patients with UC. A decrease in naïve B and T cells in the intestines and gut-homing (β7) plasmablasts in circulation of VDZ-treated patients suggested that VDZ targets gut-associated lymphoid tissue (GALT). Anti-α4β7 blockade in wild-type and photoconvertible (KikGR) mice confirmed a loss of GALT size and cellularity because of impaired cellular entry. In VDZ-treated patients with UC, treatment responders demonstrated reduced intestinal lymphoid aggregate size and follicle organization and a reduction of β7IgG plasmablasts in circulation, as well as IgG plasma cells and FcγR-dependent signaling in the intestine. GALT targeting represents a previously unappreciated mechanism of action of α4β7-targeted therapies, with major implications for this therapeutic paradigm in UC.

Citing Articles

Single-cell spatial transcriptomics of fixed, paraffin-embedded biopsies reveals colitis-associated cell networks.

Mennillo E, Lotstein M, Lee G, Johri V, Ekstrand C, Tsui J bioRxiv. 2024; .

PMID: 39605355 PMC: 11601222. DOI: 10.1101/2024.11.11.623014.

Gastrointestinal germinal center B cell depletion and reduction in IgA plasma cells in HIV-1 infection.

Cossarini F, Shang J, Krek A, Al-Taie Z, Hou R, Canales-Herrerias P Sci Immunol. 2024; 9(100):eado0090.

PMID: 39454027 PMC: 11557871. DOI: 10.1126/sciimmunol.ado0090.

A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel Disease.

Rioux J, Boucher G, Forest A, Bouchard B, Coderre L, Daneault C medRxiv. 2024; .

PMID: 39371119 PMC: 11451768. DOI: 10.1101/2024.09.19.24314034.

B cell academy of the gut: an update on gut associated germinal centre B cell dynamics.

Wichmann C, Wirthgen E, Nowosad C, Dabritz J Mol Cell Pediatr. 2024; 11(1):7.

PMID: 39147924 PMC: 11327226. DOI: 10.1186/s40348-024-00180-y.

Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.

Gabriels R, van der Waaij A, Linssen M, Dobosz M, Volkmer P, Jalal S Gut. 2024; 73(9):1454-1463.

PMID: 38580386 PMC: 11347245. DOI: 10.1136/gutjnl-2023-331696.

References

Wagner N, Lohler J, Kunkel E, Ley K, Leung E, Krissansen G . Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature. 1996; 382(6589):366-70. DOI: 10.1038/382366a0. View

Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song S . Retinoic acid imprints gut-homing specificity on T cells. Immunity. 2004; 21(4):527-38. DOI: 10.1016/j.immuni.2004.08.011. View

Wyant T, Leach T, Sankoh S, Wang Y, Paolino J, Pasetti M . Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2014; 64(1):77-83. DOI: 10.1136/gutjnl-2014-307127. View

Fedyk E, Wyant T, Yang L, Csizmadia V, Burke K, Yang H . Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012; 18(11):2107-19. DOI: 10.1002/ibd.22940. View

Morbe U, Jorgensen P, Fenton T, von Burg N, Riis L, Spencer J . Human gut-associated lymphoid tissues (GALT); diversity, structure, and function. Mucosal Immunol. 2021; 14(4):793-802. DOI: 10.1038/s41385-021-00389-4. View

Kim M, Taparowsky E, Kim C . Retinoic Acid Differentially Regulates the Migration of Innate Lymphoid Cell Subsets to the Gut. Immunity. 2015; 43(1):107-19. PMC: 4511719. DOI: 10.1016/j.immuni.2015.06.009. View

Coletta M, Paroni M, Alvisi M, De Luca M, Rulli E, Mazza S . Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2020; 14(9):1190-1201. DOI: 10.1093/ecco-jcc/jjaa035. View

Rott L, Briskin M, Butcher E . Expression of alpha4beta7 and E-selectin ligand by circulating memory B cells: implications for targeted trafficking to mucosal and systemic sites. J Leukoc Biol. 2000; 68(6):807-14. View

Reboldi A, Arnon T, Rodda L, Atakilit A, Sheppard D, Cyster J . IgA production requires B cell interaction with subepithelial dendritic cells in Peyer's patches. Science. 2016; 352(6287):aaf4822. PMC: 4890166. DOI: 10.1126/science.aaf4822. View

10.

Loftus Jr E, Feagan B, Panaccione R, Colombel J, Sandborn W, Sands B . Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020; 52(8):1353-1365. PMC: 7540482. DOI: 10.1111/apt.16060. View

11.

Rodrigo Mora J, Iwata M, Eksteen B, Song S, Junt T, Senman B . Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science. 2006; 314(5802):1157-60. DOI: 10.1126/science.1132742. View

12.

Argmann C, Hou R, Ungaro R, Irizar H, Al-Taie Z, Huang R . Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut. 2022; 72(7):1271-1287. PMC: 10014487. DOI: 10.1136/gutjnl-2021-326451. View

13.

Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W . Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2016; 67(1):43-52. DOI: 10.1136/gutjnl-2016-312293. View

14.

Uzzan M, Martin J, Mesin L, Livanos A, Castro-Dopico T, Huang R . Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat Med. 2022; 28(4):766-779. PMC: 9107072. DOI: 10.1038/s41591-022-01680-y. View

15.

Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler D . Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol. 1997; 158(5):2099-106. View

16.

Gupta R, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A . Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133(4):1099-105. PMC: 2175077. DOI: 10.1053/j.gastro.2007.08.001. View

17.

Feagan B, Rutgeerts P, Sands B, Hanauer S, Colombel J, Sandborn W . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369(8):699-710. DOI: 10.1056/NEJMoa1215734. View

18.

Castro-Dopico T, Dennison T, Ferdinand J, Mathews R, Fleming A, Clift D . Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis. Immunity. 2019; 50(4):1099-1114.e10. PMC: 6477154. DOI: 10.1016/j.immuni.2019.02.006. View

19.

Scheid J, Eraslan B, Hudak A, Brown E, Sergio D, Delorey T . Remodeling of colon plasma cell repertoire within ulcerative colitis patients. J Exp Med. 2023; 220(4). PMC: 9949229. DOI: 10.1084/jem.20220538. View

20.

Sandborn W, Cyrille M, Hansen M, Feagan B, Loftus Jr E, Rogler G . Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2018; 156(4):946-957.e18. DOI: 10.1053/j.gastro.2018.11.035. View